|
|
|
|
|
|
|
|
|
|
"Pazopanib is currently approved by the FDA to treat patients with advanced renal cell carcinoma. The research grant to NCCN will evaluate the effectiveness of pazopanib in solid tumors including renal, sarcoma, thyroid, neuroendocrine, and ovarian cancers."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.